ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

Rhea-AI Summary

ResMed will present 26 abstracts at the American Thoracic Society (ATS) 2024 conference in San Diego, highlighting the increasing prevalence of obstructive sleep apnea (OSA) and the critical role of Positive Airway Pressure (PAP) therapy. Key sessions include studies on the impact of PAP therapy on hospitalization, mortality in OSA patients, and the prevalence of OSA into 2050. The event will showcase digital innovations and patient-centric approaches in respiratory care, featuring the latest ResMed products like the AirCurve 11 Bilevel Devices and the AirFit F40 CPAP mask.

Positive

• ResMed is presenting 26 abstracts, showcasing a strong commitment to research and development.
• Studies emphasize the critical role of PAP therapy, potentially increasing product demand.
• Innovative products like AirCurve 11 and AirFit F40 are being highlighted, indicating ongoing product development.
• Digital innovations and patient-centric approaches are a focus, aligning with current healthcare trends.

Negative

• No new financial data or projections are provided, leaving investors without updated financial insights.
• The PR lacks specific market growth figures, making it difficult to assess the potential impact on revenue.

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) --

When:          May 17–22, 2024
Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101
                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101

Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:

• Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV)
  in Opioid Users – a European Registry
  • Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-B
  • Presented by Jean-Louis Pepin, MD, Grenoble Alpes University, France
• An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States into 2050
  • Monday, May 20, 9:15 a.m. - 4:15 p.m., SDCC Area C Hall A-B2
  • Presented by Elroy Boers, PhD, ResMed Science Center
• All-Cause Mortality in Obstructive Sleep Apnea
  • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B
  • Presented by Atul Malhotra, MD, University of California, San Diego
• Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database
  • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B
  • Presented by Holger Woehrle, MD, Ulm Lung Centre, Germany
• Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation – Outcomes in Patients with Treatment-Emergent or Persistent Central Sleep Apnea
  • Tuesday, May 21, 2:15 p.m. - 4:15 p.m., Marriott Marquis Pacific Ballroom 15-17
  • Presented by Michael Arzt, MD, Universitätsklinikum Regensburg, Germany
    

Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient Centricity

• Monday, May 20, 1:15 - 1:35 p.m., SDCC Innovation Hub 4
• Presented by Monica Mallampalli, Chief Executive Officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer

Booth #1442:            Featuring ResMed’s latest innovations in respiratory care:

• AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
• AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Complete list of ResMed sponsored studies to be presented at ATS 2024:

Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registry	Sunday, May 19, 2024 9:15 AM -11:15 AM
8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep Apnea	Sunday May 19, 2024 9:15 AM - 11:15 AM
Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database Analysis	Sunday May 19, 2024 9:15 AM - 4:15 PM
Tailoring Social Support to Improve PAP Therapy Usage in Obstructive Sleep Apnea	Sunday May 19, 2024 9:15 AM - 4:15 PM
Examining Alignment of Patient Medication-taking Behaviors With Inhaler Usage Recommendations in Chronic Obstructive Pulmonary Disease and Asthma	Sunday May 19, 2024 9:15 AM - 4:15 PM
Using Natural Language Processing for Qualitative Research: Insights From a Real-world Analysis	Sunday May 19, 2024 9:15 AM - 4:15 PM
A Qualitative Analysis of Perceptions and Awareness of Air Pollution and Its Health Effects in Asthma Among Asthma-care Professionals Across Southern California	Monday May 20, 2024 9:15 AM - 4:15 PM
An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States Into 2050	Monday May 20, 2024 9:15 AM - 4:15 PM
All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure Treatment	Monday May 20, 2024 2:15 PM - 4:15 PM
Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database	Monday May 20, 2024 2:15 PM - 4:15 PM
Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical Trial	Monday May 20, 2024 2:15 PM - 4:15 PM
A Digital Quality Improvement Program Delivered By Clinical Pharmacists Can Reduce Acute Care Visits In COPD	Monday May 20, 2024 2:15 PM - 4:15 PM
Hands-on Simulation Training With Home Ventilators Improves PCCM Fellow Understanding of Nocturnal NIV in Chronic Hypercapnia	Monday May 20, 2024 2:15 PM - 4:15 PM
The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data Sources	Tuesday May 21, 2024 9:15 AM - 11:15 AM
Impact of long-term domiciliary noninvasive ventilation (NIV) on severe exacerbations and survival in Patients with Chronic Obstructive Pulmonary Disease (COPD): a nationwide cohort study using multistate models	Tuesday May 21, 2024 9:15 AM - 11:15 AM
Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease in Patients With Type 2 Diabetes	Tuesday May 21, 2024 9:15 AM - 11:15 AM
Risk Factors for Severe Exacerbation Occurrence Among Patients With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway Pressure Therapy	Tuesday May 21, 2024 9:15 AM - 4:15 PM
Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 Diabetes	Tuesday May 21, 2024 2:15 PM - 4:15 PM
Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) – outcomes in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) in a European registry	Tuesday, May 21, 2024 2:15 PM – 4:15 PM
A Scenario-based Modeling Study to Project the Future Burden of COPD in the United States Accounting for the Effects of E-cigarettes	Tuesday May 21, 2024 2:15 PM - 4:15 PM
The Impact Of Weight Change On Positive Airway Pressure Use In Patients With Obstructive Sleep Apnea And Obesity	Tuesday May 21, 2024 2:15 PM - 4:15 PM
Real World GLP-1 Adherence in Patients with Treated Obstructive Sleep Apnea	Tuesday May 21, 2024 2:15 PM - 4:15 PM
Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA Trial	Tuesday May 21, 2024 2:15 PM - 4:15 PM
Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and Depression	Wednesday May 22, 2024 8:15 AM - 10:15 AM
Use of Weight Management Regimens Among Positive Airway Pressure-Treated Patients With Obstructive Sleep Apnea and Obesity	Wednesday May 22, 2024 11:00 AM - 1:00 PM
A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and Education	Wednesday May 22, 2024 11:00 AM - 1:00 PM

FAQ

What is being presented by ResMed at ATS 2024?

ResMed will present 26 abstracts on obstructive sleep apnea and the role of PAP therapy at ATS 2024.

When and where is the ATS 2024 conference being held?

The ATS 2024 conference will be held from May 17-22 at the San Diego Convention Center.

What new products will ResMed showcase at ATS 2024?

ResMed will showcase the AirCurve 11 Bilevel Devices and the AirFit F40 CPAP mask.

Which ResMed-supported study discusses the prevalence of obstructive sleep apnea in the U.S. into 2050?

Elroy Boers, PhD, will present the study on May 20 at the San Diego Convention Center.

What is a key finding from ResMed's presented research on PAP therapy?

PAP therapy significantly impacts hospitalization and mortality rates in obstructive sleep apnea patients.